Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06020014 · ClinicalTrials.gov registry record · Phase 2

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

A Phase 2 study of Asthma, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
339
Enrollment target
20
Study locations

NCT06020014 is a Phase 2 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 339 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06020014, a Phase 2 study of Asthma, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
339 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.

Conditions Studied

Asthma

Interventions

  • OTHER Placebo
  • DRUG AZD4604

Study Locations (20)

North Carolina

  • Research Site - Charlotte
  • Research Site - New Bern
  • Research Site - Salisbury
  • Research Site - Winston-Salem

California

  • Research Site - Newport Beach
  • Research Site - Sacramento

Florida

  • Research Site - Lakeland
  • Research Site - Miami

Michigan

  • Research Site - Ann Arbor
  • Research Site - Southfield

Alabama

  • Research Site - Birmingham

Arizona

  • Research Site - Chandler

Georgia

  • Research Site - Atlanta

Indiana

  • Research Site - Hammond

Trial Details

FieldValue
Enrollment Target 339 participants
Start Date 2023-11-16
Est. Completion 2025-10-28
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06020014

The ClinicalTrials.gov registry entry for NCT06020014 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 339 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (78% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06020014 reports 20 study locations spanning 14 distinct geographic areas - top geographies include North Carolina, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06020014 about?

NCT06020014 is a clinical study titled "Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA". This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-sev...

What is the current status of trial NCT06020014?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 339 participants. The study started on 2023-11-16. Estimated completion is 2025-10-28.

What conditions does trial NCT06020014 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT06020014?

The interventions under investigation include: Placebo (OTHER), AZD4604 (DRUG).

Who is sponsoring clinical trial NCT06020014?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06020014 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.